ARCH Venture Fund VII, L.P. 4
4 · Syros Pharmaceuticals, Inc. · Filed Mar 14, 2019
Insider Transaction Report
Form 4
Arch Venture Fund VII LP
10% Owner
Transactions
- Sale
Common Stock
2019-03-12$7.37/sh−40,092$295,374→ 4,432,462 total - Sale
Common Stock
2019-03-13$8.20/sh−2,820$23,122→ 4,348,051 total - Sale
Common Stock
2019-03-14$8.15/sh−43,000$350,441→ 4,305,051 total - Sale
Common Stock
2019-03-13$7.89/sh−81,591$643,443→ 4,350,871 total
Footnotes (6)
- [F1]Reflects aggregation of stock sales within the range of $7.27 to $7.51. ARCH Venture Fund VII, L.P. ("ARCH Fund VII") can provide detailed support upon request.
- [F2]Reflects aggregation of stock sales within the range of $7.19 to $8.185. ARCH Fund VII can provide detailed support upon request.
- [F3]Reflects aggregation of stock sales within the range of $8.19 to $8.22. ARCH Fund VII can provide detailed support upon request.
- [F4]Reflects aggregation of stock sales within the range of $7.915 to $8.39. ARCH Fund VII can provide detailed support upon request.
- [F5]Beneficial ownership consists of 4,305,051 shares of common stock held by ARCH Fund VII. The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
- [F6]The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by and ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.